Safety and immunogenicity of intranasal parainfluenza virus type 5 (PIV5)–vectored COVID-19 vaccine in adults and teens in an open-label phase 1 trial

Journal:

Science Advances

Published:

2025-07-04

DOI:

10.1126/sciadv.adw0896

Affiliations:

7

Authors:

20

Go to article

Institutions	Authors	Share
CyanVac LLC, United States of America (USA)	8.000000	0.40
Cincinnati Children's Hospital Medical Center (CCHMC), United States of America (USA)	3.000000	0.15
University of Louisiana at Lafayette (UL Lafayette), United States of America (USA)	3.000000	0.15
Seattle Children's Research Institute, United States of America (USA)	2.500000	0.13
University of Rochester (UR), United States of America (USA)	2.000000	0.10
The University of Georgia (UGA), United States of America (USA)	1.000000	0.05
University of Washington (UW), United States of America (USA)	0.500000	0.03

Interested in Immunology?